Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety study of Batroxobin Injection in occlusive vascular diseases
CTR20260211Phase 4Active
- Sponsor
- Beijing Tobishi Pharmaceutical Co., Ltd.
- Start
- Feb 2026
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant batroxobin in brain infarction, Buerger disease (TAO), arteriosclerosis obliterans, diabetic foot syndrome, deep vein thrombosis (DVT), sponsored by Beijing Tobishi Pharmaceutical Co., Ltd.. Started Feb 2026; status: active.
02
Drugs
recombinant batroxobin
03
Conditions
brain infarctionBuerger disease (TAO)arteriosclerosis obliteransdiabetic foot syndromedeep vein thrombosis (DVT)
Beyond the preview
Go deeper on CTR20260211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260211.